Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EPS (Basic) (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of EPS (Basic) data on record, last reported at -$73.84 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 63.42% year-over-year to -$73.84; the TTM value through Dec 2025 reached -$221.65, up 26.44%, while the annual FY2025 figure was -$221.65, 8.22% down from the prior year.
  • EPS (Basic) reached -$73.84 in Q4 2025 per VRDN's latest filing, down from -$22.88 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.71 in Q4 2021 and bottomed at -$256.72 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$39.72, with a median of -$1.44 recorded in 2023.
  • Peak YoY movement for EPS (Basic): crashed 22223.48% in 2023, then soared 97.79% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.71 in 2021, then plummeted by 61.97% to -$1.15 in 2022, then plummeted by 22223.48% to -$256.72 in 2023, then increased by 21.38% to -$201.84 in 2024, then soared by 63.42% to -$73.84 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$73.84 in Q4 2025, -$22.88 in Q3 2025, and -$124.06 in Q2 2025.